PKA-induced dimerization of the RhoGAP DLC1 promotes its inhibition of tumorigenesis and metastasis

Nature Communications

Volumn 4, Issue , 2013, Pages

  Ko, Frankie Chi Fat ^a   Chan, Lo Kong ^a   Man Fong Sze, Karen ^a   Yeung, Yin Shan ^a   Yuk Ting Tse, Edith ^a   Lu, Ping ^a   Yu, Ming Hua ^b   Oi Lin Ng, Irene ^a,c   Yam, Judy Wai Ping ^a,c  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b FUDAN UNIVERSITY PUDONG MEDICAL CENTER   (China)

^c THE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP DEPENDENT PROTEIN KINASE; DELETED IN LIVER CANCER 1 PROTEIN; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; RHOGTPASE ACTIVATING PROTEIN; SERINE; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

CANCER; ENZYME ACTIVITY; INHIBITION; MOTILITY; SIGNAL; TUMOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CANCER SURGERY; CARCINOGENESIS; CELL MOTILITY; CONTROLLED STUDY; DIMERIZATION; GENE DELETION; HEPATOMA CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; MALE; METASTASIS INHIBITION; MOUSE; NONHUMAN; PROTEIN PHOSPHORYLATION;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; CYCLIC AMP-DEPENDENT PROTEIN KINASES; DIMERIZATION; GTPASE-ACTIVATING PROTEINS; HEK293 CELLS; HUMANS; MICE; NEOPLASM METASTASIS; PHOSPHORYLATION; TRANSPLANTATION, HETEROLOGOUS; TUMOR SUPPRESSOR PROTEINS;

EID: 84875897562     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms2604     Document Type: Article

References (48)

1. Durkin, M. E., Ullmannova, V., Guan, M. & Popescu, N. C. Deleted in liver cancer 3 (DLC-3), a novel Rho GTPase-activating protein, is downregulated in cancer and inhibits tumor cell growth. Oncogene 26, 4580-4589 (2007). (Pubitemid 47037045)
2. Leung, T. H. et al. Deleted in liver cancer 2 (DLC2) suppresses cell transformation by means of inhibition of RhoA activity. Proc. Natl Acad. Sci. USA 102, 15207-15212 (2005). (Pubitemid 41513360)
3. Yuan, B. Z. et al. Cloning, characterization, and chromosomal localization of a gene frequently deleted in human liver cancer (DLC-1) homologous to rat RhoGAP. Cancer Res. 58, 2196-2199 (1998).
4. Liao, Y. C. & Lo, S. H. Deleted in liver cancer-1 (DLC-1): a tumor suppressor not just for liver. Int. J. Biochem. Cell Biol. 40, 843-847 (2008). (Pubitemid 351329658)
5. Goodison, S. et al. The RhoGAP protein DLC-1 functions as a metastasis suppressor in breast cancer cells. Cancer Res. 65, 6042-6053 (2005). (Pubitemid 40994388)
6. Ko, F. C. et al. Akt phosphorylation of deleted in liver cancer 1 abrogates its suppression of liver cancer tumorigenesis and metastasis. Gastroenterology 139, 1397-1407 (2010).
7. Shih, Y. P., Liao, Y. C., Lin, Y. & Lo, S. H. DLC1 negatively regulates angiogenesis in a paracrine fashion. Cancer Res. 70, 8270-8275 (2010).
8. Xue, W. et al. DLC1 is a chromosome 8p tumor suppressor whose loss promotes hepatocellular carcinoma. Genes Dev. 22, 1439-1444 (2008). (Pubitemid 351793078)
9. Healy, K. D. et al. DLC-1 suppresses non-small cell lung cancer growth and invasion by RhoGAP-dependent and independent mechanisms. Mol. Carcinog. 47, 326-337 (2008). (Pubitemid 351614573)
10. Vega, F. M. & Ridley, A. J. Rho GTPases in cancer cell biology. FEBS Lett. 582, 2093-2101 (2008).
11. Lahoz, A. & Hall, A. DLC1: a significant GAP in the cancer genome. Genes Dev. 22, 1724-1730 (2008). (Pubitemid 351915495)
12. Qian, X. et al. Oncogenic inhibition by a deleted in liver cancer gene requires cooperation between tensin binding and Rho-specific GTPase-activating protein activities. Proc. Natl Acad. Sci. USA 104, 9012-9017 (2007). (Pubitemid 47175428)
13. Wong, C. M. et al. Rho GTPase-activating protein deleted in liver cancer suppresses cell proliferation and invasion in hepatocellular carcinoma. Cancer Res. 65, 8861-8868 (2005).
14. Liao, Y. C., Shih, Y. P. & Lo, S. H. Mutations in the focal adhesion targeting region of deleted in liver cancer-1 attenuate their expression and function. Cancer Res. 68, 7718-7722 (2008).
15. Yang, X., Popescu, N. C. & Zimonjic, D. B. DLC1 interaction with S100A10 mediates inhibition of in vitro cell invasion and tumorigenicity of lung cancer cells through a RhoGAP-independent mechanism. Cancer Res. 71, 2916-2925 (2011).
16. Zhong, D. et al. The SAM domain of the RhoGAP DLC1 binds EF1A1 to regulate cell migration. J. Cell Sci. 122, 414-424 (2009).
17. Li, G. et al. Full activity of the deleted in liver cancer 1 (DLC1) tumor suppressor depends on an LD-like motif that binds talin and focal adhesion kinase (FAK). Proc. Natl Acad. Sci. USA 108, 17129-17134 (2011).
18. Yang, X. Y. et al. p120Ras-GAP binds the DLC1 Rho-GAP tumor suppressor protein and inhibits its RhoA GTPase and growth-suppressing activities. Oncogene 28, 1401-1409 (2009).
19. Erlmann, P. et al. DLC1 activation requires lipid interaction through a polybasic region preceding the RhoGAP domain. Mol. Biol. Cell 20, 4400-4411 (2009).
20. Scholz, R. P. et al. DLC1 interacts with 14-3-3 proteins to inhibit RhoGAP activity and block nucleocytoplasmic shuttling. J. Cell Sci. 122, 92-102 (2009).
21. Scholz, R. P. et al. The tumor suppressor protein DLC1 is regulated by PKDmediated GAP domain phosphorylation. Exp. Cell Res. 317, 496-503 (2011).
22. Kim, T. Y., Vigil, D., Der, C. J. & Juliano, R. L. Role of DLC-1, a tumor suppressor protein with RhoGAP activity, in regulation of the cytoskeleton and cell motility. Cancer Metastasis Rev. 28, 77-83 (2009).
23. Chan, L. K., Ko, F. C., Sze, K. M., Ng, I. O. & Yam, J. W. Nuclear-targeted deleted in liver cancer 1 (DLC1) is less efficient in exerting its tumor suppressive activity both in vitro and in vivo. PLoS One 6, e25547 (2011).
24. Yam, J. W., Ko, F. C., Chan, C. Y., Jin, D. Y. & Ng, I. O. Interaction of deleted in liver cancer 1 with tensin2 in caveolae and implications in tumor suppression. Cancer Res. 66, 8367-8372 (2006). (Pubitemid 44449146)
25. Liao, Y. C., Si, L., deVere White, R. W. & Lo, S. H. The phosphotyrosineindependent interaction of DLC-1 and the SH2 domain of cten regulates focal adhesion localization and growth suppression activity of DLC-1. J. Cell Biol. 176, 43-49 (2007). (Pubitemid 46041679)
26. Chan, L. K., Ko, F. C., Ng, I. O. & Yam, J. W. Deleted in liver cancer 1 (DLC1) utilizes a novel binding site for Tensin2 PTB domain interaction and is required for tumor-suppressive function. PLoS One 4, e5572 (2009).
27. Wong, C. M., Lee, J. M., Ching, Y. P., Jin, D. Y. & Ng, I. O. Genetic and epigenetic alterations of DLC-1 gene in hepatocellular carcinoma. Cancer Res. 63, 7646-7651 (2003). (Pubitemid 37466690)
28. Jaffe, A. B. & Hall, A. Rho GTPases in transformation and metastasis. Adv. Cancer Res. 84, 57-80 (2002). (Pubitemid 34188194)
29. Scholz, R. P. et al. The tumor suppressor protein DLC1 is regulated by PKDmediated GAP domain phosphorylation. Exp. Cell Res. 317, 496-503 (2010).
30. Li, H. et al. Solution structures, dynamics, and lipid-binding of the sterile alphamotif domain of the deleted in liver cancer 2. Proteins 67, 1154-1166 (2007). (Pubitemid 46753960)
31. Lukasik, D., Wilczek, E., Wasiutynski, A. & Gornicka, B. Deleted in liver cancer protein family in human malignancies (Review). Oncol. Lett. 2, 763-768 (2011).
32. Guo, S. & Bao, S. srGAP2 arginine methylation regulates cell migration and cell spreading through promoting dimerization. J. Biol. Chem. 285, 35133-35141 (2010).
33. Wang, Y. et al. Plexins are GTPase-activating proteins for Rap and are activated by induced dimerization. Sci. Signal. 5, ra6 (2012).
34. Cao, X., Voss, C., Zhao, B., Kaneko, T. & Li, S. S. Differential regulation of the activity of deleted in liver cancer 1 (DLC1) by tensins controls cell migration and transformation. Proc. Natl Acad. Sci. USA 109, 1455-1460 (2012).
35. Howe, A. K. Regulation of actin-based cell migration by cAMP/PKA. Biochim. Biophys. Acta 1692, 159-174 2004. (Pubitemid 38891772)
36. Newell-Litwa, K. A. & Horwitz, A. R. Cell migration: PKA and RhoA set the pace. Curr. Biol. 21, R596-R598 (2011).
37. Tkachenko, E. et al. Protein kinase A governs a RhoA-RhoGDI protrusionretraction pacemaker in migrating cells. Nat. Cell Biol. 13, 660-667 (2011).
38. Ellerbroek, S. M., Wennerberg, K. & Burridge, K. Serine phosphorylation negatively regulates RhoA in vivo. J. Biol. Chem. 278, 19023-19031 (2003). (Pubitemid 36799287)
39. Diviani, D., Abuin, L., Cotecchia, S. & Pansier, L. Anchoring of both PKA and 14-3-3 inhibits the Rho-GEF activity of the AKAP-Lbc signaling complex. EMBO J. 23, 2811-2820 (2004). (Pubitemid 39013553)
40. Linnerth, N. M., Greenaway, J. B., Petrik, J. J. & Moorehead, R. A. cAMP response element-binding protein is expressed at high levels in human ovarian adenocarcinoma and regulates ovarian tumor cell proliferation. Int. J. Gynecol. Cancer 18, 1248-1257 (2008).
41. Mantovani, G. et al. High expression of PKA regulatory subunit 1A protein is related to proliferation of human melanoma cells. Oncogene 27, 1834-1843 (2008). (Pubitemid 351430825)
42. Mantovani, G. et al. Different expression of protein kinase A (PKA) regulatory subunits in cortisol-secreting adrenocortical tumors: relationship with cell proliferation. Exp. Cell Res. 314, 123-130 (2008). (Pubitemid 350180780)
43. O'Connor, K. L., Shaw, L. M. & Mercurio, A. M. Release of cAMP gating by the alpha6beta4 integrin stimulates lamellae formation and the chemotactic migration of invasive carcinoma cells. J. Cell Biol. 143, 1749-1760 (1998). (Pubitemid 29006517)
44. Lee, J. et al. Cyclic AMP induces inhibition of cyclin A expression and growth arrest in human hepatoma cells. Biochim. Biophys. Acta 1449, 261-268 (1999). (Pubitemid 29164383)
45. Liu, L., Xie, Y. & Lou, L. Cyclic AMP inhibition of proliferation of hepatocellular carcinoma cells is mediated by Akt. Cancer Biol. Ther. 4, 1240-1247 (2005).
46. Xie, J. et al. cAMP inhibits mammalian target of rapamycin complex-1 and-2 (mTORC1 and 2) by promoting complex dissociation and inhibiting mTOR kinase activity. Cell Signal. 23, 1927-1935 (2011).
47. Veugelers, M. et al. Comparative PRKAR1A genotype-phenotype analyses in humans with Carney complex and prkar1a haploinsufficient mice. Proc. Natl Acad. Sci. USA 101, 14222-14227 (2004). (Pubitemid 39305057)
48. Bertherat, J. et al. Mutations in regulatory subunit type 1A of cyclic adenosine 5'-monophosphate-dependent protein kinase (PRKAR1A): phenotype analysis in 353 patients and 80 different genotypes. J. Clin. Endocrinol. Metab. 94, 2085-2091 (2009).